
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis is supported by a highly strategic acquisition by Tempus AI, which validates the company’s genomic sequencing and analytics platform and underscores the value of its NeXT Personal MRD franchise. Its fundamentals are improving, with Q1'26 molecular clinical test volume of 7,815 rising 258% year over year and 26% quarter over quarter, while Q1 Dx revenue of $1.4M exceeded expectations and 1,000+ oncologists are now ordering the test. The company also benefits from Medicare coverage, growing biopharma demand, and a 2Q26 revenue guide of $22.4M versus $16.8M consensus, suggesting expanding commercial traction and stronger visibility into future growth.
Bears say
Personalis is viewed negatively because its low gross margin and negative operating margin, combined with significant cash burn, suggest the business still lacks durable profitability even after Q1'26 revenue of $15.5M beat expectations. The outlook is further pressured by execution risk in clinical diagnostics, where Medicare or commercial payer coverage for the MRD test could fall short, while biopharma ordering patterns remain volatile and large pharma demand for personalized cancer vaccines could soften. In addition, the all-stock acquisition structure introduces closing risk because PSNL can terminate if TEM falls below $46.00 per share, and the current $48.25 level leaves only limited cushion.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares